1. In Vivo
  2. >>Business Strategy

Schering-Plough, Novartis and Foradil: Measuring the Need for New Products

Schering's willingness to take over the marketing responsibilities for Novartis's Foradil respiratory drug, which has been largely superseded by combination products, to some degree measures the depths of Schering's troubles. But it also indicates the kinds of competition small-company in-licensers are likely to face. A whole industry of in-licensing focused players has grown up to sell the non-core products of Big Pharma: if Schering is any indication, the competition for these products is likely to get even more intense.

Much of the attention in licensing circles goes to the big deals with big dollars attached to them. But another way to measure the desperate need for late-stage products among Big Pharma is to look at the deals for drugs with only middling commercial prospects.

Novartis AG had spent quite a lot developing its long-acting beta agonist, formoterol fumarate (Foradil) for the American market—including...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

More from In Vivo

Execs On The Move: June 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.